Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development.
The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
MiR-30a inhibits Th17 differentiation and demyelination of EAE mice by targeting the IL-21R.
The safety of exercise training in multiple sclerosis: A systematic review.
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
The risk of Bipolar Disorders in Multiple Sclerosis.
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
Variables associated with patient activation in persons with multiple sclerosis.
▼Dimethyl fumarate for relapsing-remitting multiple sclerosis.
Wnt Signaling in the Pathogenesis of Multiple Sclerosis-Associated Chronic Pain.
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Individual variability in speed of information processing: An index of cognitive impairment in multiple sclerosis.
Effect of wearing a dorsiflexion assist orthosis on mobility, perceived fatigue and exertion during the six-minute walk test in people with multiple sclerosis: a randomised cross-over protocol.
Overview of treatment options in multiple sclerosis.
Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
Clinically isolated syndromes and the relationship to multiple sclerosis.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Pages